Based on Your Reading:
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Written by Karen Selby, RN | Medically Reviewed By Dr. Daniel Landau | Edited By Walter Pacheco | Last Update: July 22, 2024
Tremelimumab is known by the brand name Imjudo. In late 2022, Tremelimumab received approval to treat two types of cancer. These cancers include non-small cell lung cancer and inoperable liver cancer. The U.S. Food and Drug Administration approved it in combination with other drugs.
In April 2015, tremelimumab received orphan drug designation by the FDA to treat mesothelioma. Orphan drug designation is not the same as FDA approval. It helps pharmaceutical companies move a drug designed to treat rare diseases through the approval process.
Orphan designation does not mean the drug is safe or effective. It also does not guarantee FDA approval.
Clinical trials began testing tremelimumab on mesothelioma in 2013. So far, research has proven the drug helps some people with mesothelioma.
Research is ongoing to determine which mesothelioma patients may benefit the most from this drug. It might be most effective when combined with other immunotherapy drugs.
In 2017, mesothelioma survivor Jim McWhorter joined a clinical trial testing tremelimumab. It was combined with durvalumab, another immunotherapy drug. He initially responded quite well. The drugs stopped his tumor growth for months. Eventually, the cancer returned and McWhorter had to leave that trial in search of other options to control his cancer.
In 2021, a study assessed patients four years after treatment with tremelimumab and durvalumab. About 20% of patients were alive at 36 months, and 15% of patients survived for 48 months or longer. The results show the treatment combination boosted long-term survival.
The FDA has approved tremelimumab in combination with other drugs to treat non-small cell lung cancer and inoperable liver cancer.
Clinical trials of tremelimumab have shown it may help control several different types of cancer. New clinical trials are testing it in combination with several anti-cancer drugs with the hope of finding a magic combination for mesothelioma.
Tremelimumab has been tested on a variety of cancers including mesothelioma, lung cancer, melanoma, liver cancer, bladder cancer and head and neck cancer.
Small studies indicate about half of mesothelioma patients respond to tremelimumab and about half live at least one year on the drug. Several clinical trials continue to test the drug in mesothelioma patients.
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Tremelimumab is a human antibody that helps the immune system fight cancer.
Antibodies are proteins in the immune system that recognize and attack foreign invaders. Examples include bacteria, viruses and cancer cells.
The tremelimumab antibody activates an immune cell known as cytotoxic T lymphocytes (CTLs), or killer T cells. These immune cells kill cancer cells.
An increase in activated killer T cells helps a person’s immune system fight cancer.
Tremelimumab is considered an immune checkpoint blocker because it blocks a protein called CTLA-4, which deactivates killer T cells.
By blocking CTLA-4, tremelimumab activates killer T cells so they can get to work fighting cancer.
Tremelimumab Information | |
---|---|
Name | Tremelimumab |
Manufacturer | AstraZeneca |
Administration Route | IV |
Active Ingredient | Tremelimumab |
Drug Class | Immune checkpoint blocker, monoclonal antibody |
Interacting Drug | Ask your doctor |
Alternate Names | Ticilimumab, anti-CTLA 4 monoclonal antibody-Pfizer, CP-675, CP-675206 |
Dosage | 1 mg/kg, 10 mg/kg, 15 mg/kg or 75 mg |
Medical Studies | MEDI4736 or MEDI4736 + Tremelimumab in Surgically Resectable Malignant Pleural Mesothelioma |
FDA Warning | Skin reaction, skin rash, itching sensation, diarrhea, nausea, fatigue and immune-mediated disorders |
Tremelimumab may help people live longer with mesothelioma, but the drug may also cause side effects. The side effects range from mild to severe.
Common side effects include:
People see immunotherapy as a more natural approach to fighting cancer because it activates the immune system. But this does not mean serious side effects aren’t a possibility.
Research shows tremelimumab has the potential to cause life-threatening side effects. Serious side effects include holes in the intestines and obstruction of the small intestine. Inflammation of the colon and skin ulcers are possible as well.
Call your doctor right away if you notice any mild or serious side effects. Don’t try to tough it out, even with mild side effects.
There are therapies and medications to treat every side effect. Immediate treatment of side effects helps keep them in control.
Several landmark trials have shown tremelimumab can stop mesothelioma tumors from growing for periods of time.
The problem is tremelimumab seems to work well for only a little while. The drug usually stops cancer growth for several months before it stops working altogether, a reason why it hasn’t been approved to treat mesothelioma.
Initial studies of the drug produced impressive results that haven’t been replicated in larger clinical trials.
For example, two small Italian studies reported tremelimumab stopped cancer growth in about half of the mesothelioma participants. Around half of the patients lived at least a year in both studies. Nearly 37 percent of participants survived at least two years in one of the studies.
The largest study to date of tremelimumab in mesothelioma patients did not reach its goal of extending overall survival.
AstraZeneca stopped the trial in 2016 when they realized it was not working well enough. This study used the drug alone rather than in combination with other drugs.
Researchers suggested more trials that combine drugs are necessary to see how well tremelimumab may work against mesothelioma.
That research is underway at several U.S. mesothelioma specialty centers and internationally.
The jury is still out on whether tremelimumab will prove to be an effective mesothelioma treatment.
Good research has proven it isn’t effective enough on its own to use as a single therapy against mesothelioma. However, combining tremelimumab and durvalumab has proven more effective against lung cancer than tremelimumab alone.
This optimistic outcome has researchers hopeful for similar results for mesothelioma patients.
This Page Contains 14 Cited Articles
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
Selby, K. (2024, July 22). Tremelimumab. Asbestos.com. Retrieved December 3, 2024, from https://www.asbestos.com/treatment/immunotherapy/tremelimumab/
Selby, Karen. "Tremelimumab." Asbestos.com, 22 Jul 2024, https://www.asbestos.com/treatment/immunotherapy/tremelimumab/.
Selby, Karen. "Tremelimumab." Asbestos.com. Last modified July 22, 2024. https://www.asbestos.com/treatment/immunotherapy/tremelimumab/.
A medical doctor who specializes in mesothelioma or cancer treatment reviewed the content on this page to ensure it meets current medical standards and accuracy.
Please read our editorial guidelines to learn more about our content creation and review process.
Dr. Daniel Landau is the Medical Director of Virtual Hematology at the Medical University of South Carolina in Charleston. He has served in several leadership roles and developed telehealth services at several cancer centers.
Mesothelioma Center - Vital Services for Cancer Patients & Families doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.